Are ARA-290 and cibinetide different compounds?
The cited clinical records use ARA-290 and cibinetide for the same research peptide. The name “erythropoietin-derived” describes design context and does not make it erythropoietin.
ARA-290 Reconstitution Calculator
Classification: Investigational peptide engineered from erythropoietin-related structural signaling, without treating it as erythropoietin.
Overview
ARA-290, also called cibinetide, is a synthetic peptide designed from a region of erythropoietin associated with tissue-protective signaling research. The literature distinguishes this research peptide from erythropoietin’s hematopoietic activity. That distinction matters: a structural relationship does not make ARA-290 interchangeable with erythropoietin, and it does not establish a product’s identity or quality.
PepLedger’s calculator handles only visitor-entered mass and liquid-volume values. It can show the concentration implied by those values and the liquid volume represented by another entered mass amount. It cannot determine whether an ARA-290 label is genuine, whether a material is suitable for a person, or whether research findings apply outside their study setting.
The label “cibinetide” appears in clinical literature and trial records, while “ARA-290” is used in both experimental and clinical research. Naming consistency is not a substitute for a verified label. Enter the spelling and units shown by the relevant source, and treat an unresolved identity or unit as an information gap rather than something arithmetic can repair.
Research context
A PubMed-indexed human study examined ARA-290 in people with type 2 diabetes and reported metabolic and neuropathic outcomes under a controlled research design. Another phase 2 publication studied cibinetide in diabetic macular edema. ClinicalTrials.gov records also show studies concerning metabolic and cognitive or neural questions. Those records establish that the peptide has been investigated in people; they do not establish benefit, suitability, or authorization.
Preclinical papers explore signaling and nervous-system mechanisms, but findings in cell or animal systems cannot be converted into a personal conclusion. PepLedger therefore describes the research relationship cautiously and does not present claims about pain, neuropathy, tissue repair, cognition, or any other outcome.
Evidence and regulatory status
The sources below are PubMed publications and ClinicalTrials.gov records. They are useful for identifying the peptide and its study history, but none is an approval document. No FDA, EMA, or other national authorization is asserted here. The absence of an asserted authorization should not be interpreted as a legal opinion about any particular jurisdiction.
Evidence interpretation remains constrained by study size, endpoints, population, formulation, and follow-up. A named research intervention in a trial is not evidence that independently labeled material has equivalent composition. Trial registration is also not a safety or efficacy determination.
Unit notes
Mass may be entered in mg or mcg, with 1 mg = 1,000 mcg. Liquid volume is entered in mL. A concentration is meaningful only in relation to both the entered mass and the entered volume.
U-100 means 100 units per mL; U-40 means 40 units per mL. These are liquid-scale definitions, not ARA-290 quantities. A custom scale uses only the units-per-mL value supplied by the visitor. Package and volume shortcuts are neutral data-entry conveniences.
Limitations
- Only arithmetic is within scope: unit normalization, concentration, represented liquid volume, and syringe-scale conversion. The tool does not assess the peptide’s biological activity, sterility, purity, identity, compatibility, or regulatory status.
- Do not use a result to infer how a research product should be prepared or used. If a label uses an unfamiliar unit, omits liquid volume, or conflicts with a verified document, the calculator cannot resolve that conflict.
Frequently asked questions
What does this calculator calculate?
It calculates concentration and represented liquid volume from the visitor’s entered mass and liquid volume, then expresses that volume on the selected syringe scale.
Does the calculator make ARA-290 research findings personal?
No. Arithmetic cannot establish identity, purity, biological activity, safety, suitability, or whether study findings apply to a visitor.
Is cibinetide an approved medicine?
The sources listed here document research studies and do not provide an approval for cibinetide. PepLedger makes no approved-use claim.
Does PepLedger determine an amount?
No. PepLedger performs arithmetic using values entered by the visitor and does not determine or recommend an amount.
Why does liquid volume matter to concentration?
Concentration is mass divided by liquid volume. Changing the entered volume changes that relationship, so the same vial mass can produce a different calculated concentration.
Sources and official references
- ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes — PubMed (2014)
- A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema — PubMed (2020)
- Effects of ARA 290, an Erythropoietin Analogue, in Prediabetes and Type 2 Diabetes — ClinicalTrials.gov (2013)
- Cognitive and Neural Effects of ARA290 — ClinicalTrials.gov (2014)
Calculation methodology
PepLedger calculates concentration, liquid volume and syringe-scale position exclusively from the values you enter. It does not choose or recommend an amount.
View our calculation methodology and editorial standards
Last updated: September 13, 2026